For U.S. healthcare professionals only

Hemophilia is a piece of them.

Not all of them.

Indications and Limitations of Use: ADYNOVATE® [Antihemophilic factor (Recombinant), PEGylated] is a human antihemophilic factor indicated for use in children and adults with hemophilia A for the control and prevention of bleeding episodes. ADYNOVATE is not indicated for the treatment of von Willebrand disease.1

*In clinical trials, ADYNOVATE demonstrated the ability to help prevent bleeding episodes using a prophylaxis regimen.

ADYNOVATE has a simple, twice-weekly dosing schedule on the same 2 days each week, which can help personalize treatment so that your patients have more time to spend doing the other things that make them who they are.1
Pictures of an hemophilia patient throughout different stages of his life
ADYNOVATE molecule including PEG attachment

Designed to Extend FVIII
Circulation Time

ADYNOVATE is built on the ADVATE® [Antihemophilic Factor (Recombinant)] molecule, a proven treatment in hemophilia A patients. Created with PEGylation technology, ADYNOVATE was designed to stay in circulation longer than ADVATE, to provide factor coverage.†1-3

Proprietary PEGylation Technology exclusively licensed from Nektar Therapeutics.

Watch the MOA video

SELECTED IMPORTANT RISK INFORMATION

CONTRAINDICATIONS: Prior anaphylactic reaction to ADYNOVATE, to the parent molecule (ADVATE [Antihemophilic Factor (Recombinant)]), mouse or hamster protein, or excipients of ADYNOVATE (e.g. Tris, mannitol, trehalose, glutathione, and/or polysorbate 80).
See Detailed Important Risk Information below.

ADYNOVATE—a treatment that's approved in children and adults with hemophilia A1

Calendar Icon - Weekly dosing happens the same days each week

AS A 2X/WEEK
PROPHYLAXIS TREATMENT

See the data
Fast watch icon - treatment is available when you need it

AS AN ON-DEMAND
TREATMENT

See the results
Gurney icon - Adynovate [Antihemophilic Factor (Recombinant), PEGylated] is indicated for surgical use and can be used before, during or after a procedure

AS PERIOPERATIVE
MANAGEMENT

Learn more

ADYNOVATE is not indicated for the treatment of von Willebrand Disease.

SELECTED IMPORTANT RISK INFORMATION

WARNINGS & PRECAUTIONS

Neutralizing Antibodies: Formation of neutralizing antibodies (inhibitors) to factor VIII can occur following administration of ADYNOVATE. Monitor patients regularly for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests. Perform an assay that measures factor VIII inhibitor concentration if the plasma factor VIII level fails to increase as expected, or if bleeding is not controlled with expected dose.
See Detailed Important Risk Information below.